Biology and Genomic Distinctions in Metastatic Urothelial Carcinoma and Upper Tract Urothelial Cancers - Andrew Hsieh - Bishoy Faltas - Matthew Galsky
Petros Grivas hosts Matthew Galsky, Bishoy Faltas and Andrew Hsieh in a discussion about their research programs and recent findings that drive closer to providing personalized medicine in the treatments in metastatic urothelial carcinoma and upper tract urothelial cancers. Groundbreaking work is discussed in this podcast and the three platform papers that discuss this evidence in more detail are linked below as related content.
Petros Grivas, MD Ph.D., Associate Professor, Clinical Director of Genitourinary Cancers Program, University of Washington, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
Matthew Galsky, MD, Director, Genitourinary Medical Oncology and Associate Medical Director at the Cancer Clinical Trials Office at Mount Sinai Health System and The Tisch Cancer Institute
Andrew Hsieh, MD, Assistant Member, Human Biology Division, Fred Hutch, Assistant Member, Clinical Research Division, Fred Hutch, Assistant Professor, Department of Medicine, University of Washington, Affiliate Faculty, Genome Sciences, University of Washington, Dr. Andrew Hsieh is a physician-scientist who balances the clinical care of prostate and bladder cancer patients with running a research laboratory at Fred Hutch. He studies how cells build proteins — and how cancer cells can co-opt this process to better grow and spread. Through these studies, his team aims to develop new drugs that can selectively target these changes and ultimately impact the lives of patients with cancer.
Bishoy M. Faltas, MD, Director of Bladder Cancer Research, Englander Institute for Precision Medicine, Weill Cornell Medicine
Genomic Distinctions Between Metastatic Lower and Upper Tract Urothelial Carcinoma Revealed Through Rapid Autopsy
First-of-its-kind Rapid Autopsy Program Helps Reveal Deadly Disease’s Potential Vulnerabilities
Distinctive Biology Drives New Therapies in Upper Urinary Tract Cancers
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling